Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04323436
Title Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Capmatinib + Spartalizumab

Capmatinib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL

Facility Status City State Zip Country Details
Massachusetts General Hospital Liver and Kidney TX Boston Massachusetts 02114 United States Details
Novartis Investigative Site Leuven 3000 Belgium Details
Novartis Investigative Site Montreal Quebec H4A 3J1 Canada Details
Novartis Investigative Site Lille 59000 France Details
Novartis Investigative Site Paris 75679 France Details
Novartis Investigative Site Pierre Benite Cedex 69495 France Details
Novartis Investigative Site Berlin 13125 Germany Details
Novartis Investigative Site Gerlingen 70839 Germany Details
Novartis Investigative Site Koeln 50937 Germany Details
Novartis Investigative Site Tübingen 72076 Germany Details
Novartis Investigative Site Bologna BO 40138 Italy Details
Novartis Investigative Site Osaka Sayama Osaka 589 8511 Japan Details
Novartis Investigative Site Seoul 03080 Korea, Republic of Details
Novartis Investigative Site Barcelona Catalunya 08036 Spain Details
Novartis Investigative Site Valencia Comunidad Valenciana 46014 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field